title: Evaluation of serum biomarkers IL-17 and CTX for BRONJ: a pilot clinical case-control study.
abstract: A serious complication of bisphosphonate (BP) therapy is BP-related osteonecrosis of the jaw (BRONJ). Currently, no biomarkers exist to identify patients at risk. We evaluated whether interleukin-17 and C-telopeptide correlate with BRONJ development. We conducted a case-control study using patients with a history of BP therapy. Quantitative enzyme-linked immunosorbent assay and Student's t-test were done. Both markers were significantly higher in BRONJ, suggesting altered immune responses and bone remodeling may play roles in BRONJ development.
authors: Herman Ostrow School of Dentistry, University of Southern California, USA. peterbclee@gmail.com
authors: Peter B
authors: PB
authors: Lee
authors: Herman Ostrow School of Dentistry, University of Southern California, USA.
authors: Andrew S
authors: AS
authors: Kiss
authors: Herman Ostrow School of Dentistry, University of Southern California, USA.
authors: Andrew L
authors: AL
authors: Nguyen
authors: Herman Ostrow School of Dentistry, University of Southern California, Center for Craniofacial Molecular Biology, USA.
authors: Songtao
authors: S
authors: Shi
authors: University of Southern California Center for Biofilms, USA.
authors: Parish P
authors: PP
authors: Sedghizadeh
authors: Department of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania, Philadelphia, USA.
authors: D
authors: D
authors: Le Anh
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000097:blood* / Q000276:immunology*; D016022:Case-Control Studies; D024042:Collagen Type I / Q000097:blood*; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000097:blood*; D008297:Male; D010455:Peptides / Q000097:blood*; D010865:Pilot Projects
chemical_list: D024042:Collagen Type I; D020381:Interleukin-17; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide